Disease · MONDO_0006256
invasive breast carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. invasive breast carcinoma. Diseases, record MONDO_0006256. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006256
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
infiltrating breast cancer, infiltrating breast carcinoma, infiltrating carcinoma of breast, infiltrating carcinoma of the breast, invasive breast cancer, invasive carcinoma of breast, invasive carcinoma of the breast, invasive mammary carcinoma
- Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TRASTUZUMAB | CHEMBL1201585 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANASTROZOLE | CHEMBL1399 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 76
See all 76 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | Phase 3 | 3,270 | 2020-09-23 | HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7 | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00944047 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | Phase 2 | 32 | 2018-04-23 | Breast Cancer | CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | Phase 2 | 12 | 2017-08-01 | Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma | MK-2206 | Its record names the disease | ClinicalTrials.gov |
| NCT00354640 | Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer | Phase 2 | 11 | 2013-06-24 | Breast Cancer | ANASTROZOLE, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | Phase 2 | 120 | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | METFORMIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00777673 | Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | Phase 2 | 60 | Breast Cancer | BEVACIZUMAB, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05664893 | Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) | Phase 1/2 | 0 | HER2 Negative Breast Cancer Not Immediately Operated | RIBOCICLIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006256
GET https://conductscience.org/api/diseases/v1/MONDO_0006256/targets?page=2